Evidence map›Paper›PMID 40937451›Full record

ArticleWorld journal of gastroenterology2025

Dopamine receptor D1-mediated suppression of liver fibrosis

Hai-Yan Wang, Man-Man Qi, Kai Zhang, Yu-Zhao Zhu, Jian Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hai-Yan WangSchool of Medicine, Shanghai University Baoshan Campus, Shanghai 200444, China.
Man-Man QiSchool of Medicine, Shanghai University, Shanghai 200444, China.
Kai ZhangSchool of Medicine, Shanghai University, Shanghai 200444, China.
Yu-Zhao ZhuShanghai Universal Medical Imaging Diagnostic Center, Shanghai 200233, China.
Jian ZhangDepartment of Nuclear Medicine, Universal Medical Imaging Diagnostic Center, Shanghai University, Shanghai 200233, China. abiaoxp@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundYes-associated protein 1 (YAP1), a downstream transcriptional coactivator regulated by the Hippo signaling pathway, has been shown to be involved in liver fibrosis. YAP activity is modulated by G-protein coupled receptors, including Gα s-coupled protein dopamine receptor D1 (DRD1). Levodopa, a dopamine precursor, activates DRD1 on cell surface, triggering its downstream signaling pathway.

aimTo investigate the therapeutic effect of levodopa and the downstream mechanism on carbon tetrachloride (CCl

methodsSD rats were intraperitoneally injected with 40% CCl

resultsCompared with the controls, levodopa-treated rats showed a decrease in the proportion of collagen in the liver and a recovery from liver fibrosis (

conclusionThis was the first study to demonstrate that levodopa attenuates CCl

Indexed as

Adaptor Proteins, Signal TransducingLevodopaLiver CirrhosisLiver Cirrhosis, ExperimentalReceptors, Dopamine D1AnimalsCarbon TetrachlorideHippo Signaling PathwayHumansLiverMalePhosphorylationProtein Serine-Threonine KinasesRatsRats, Sprague-DawleySignal TransductionAdaptor Proteins, Signal TransducingCarbon TetrachlorideLevodopaProtein Serine-Threonine KinasesReceptors, Dopamine D1Yap1 protein, ratYAP-Signaling ProteinsDopamine receptor D1Hippo/Yes-associated protein 1 signaling pathwayLevodopaLiver fibrosisYes1 associated transcriptional regulator

Identifiers

PMID40937451
PMCPMC12421406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.